Îñòàâüòå ññûëêó íà ýòó ñòðàíèöó â ñîöñåòÿõ:

Ïîèñê ïî áàçå äîêóìåíòîâ:

 

ÏÐÀÂÈÒÅËÜÑÒÂÎ ÌÎÑÊÂÛ

ÄÅÏÀÐÒÀÌÅÍÒ ÇÄÐÀÂÎÎÕÐÀÍÅÍÈß

 

ÏÈÑÜÌÎ

 

24 àâãóñòà 2005 ã.

 

N 1-18-185

 

ÎÁ ÓÏÎÐßÄÎ×ÅÍÈÈ ÐÎÇÍÈ×ÍÛÕ ÖÅÍ ÍÀ ËÅÊÀÐÑÒÂÅÍÍÛÅ ÑÐÅÄÑÒÂÀ

 ÃÎÑÓÄÀÐÑÒÂÅÍÍÛÕ ÓÍÈÒÀÐÍÛÕ ÀÏÒÅ×ÍÛÕ ÏÐÅÄÏÐÈßÒÈßÕ

ÃÎÐÎÄÀ ÌÎÑÊÂÛ

 

Äåïàðòàìåíò çäðàâîîõðàíåíèÿ ãîðîäà Ìîñêâû ñîîáùàåò, ÷òî ïðè ïðîâåäåíèè ïðîâåðîê ãîñóäàðñòâåííûõ óíèòàðíûõ àïòå÷íûõ ïðåäïðèÿòèé âûÿâëåíû çíà÷èòåëüíûå êîëåáàíèÿ öåí íà àíàëîãè÷íûå ëåêàðñòâåííûå ñðåäñòâà. Ïðè àíàëèçå öåí íà îòäåëüíûå ãðóïïû ëåêàðñòâåííûõ ñðåäñòâ ðàçíèöà ïî íåêîòîðûì ïîçèöèÿì äîñòèãàåò 70%.

Ñ öåëüþ îáåñïå÷åíèÿ äîñòóïíîñòè ëåêàðñòâåííûõ ñðåäñòâ â ãîñóäàðñòâåííûõ óíèòàðíûõ àïòå÷íûõ ïðåäïðèÿòèÿõ ãîðîäà Ìîñêâû Äåïàðòàìåíò çäðàâîîõðàíåíèÿ ãîðîäà Ìîñêâû ïðåäëàãàåò ñ 12.09.2005 ã. óñòàíîâèòü ïðåäåëüíûå ðîçíè÷íûå öåíû íà íîìåíêëàòóðó ëåêàðñòâåííûõ ñðåäñòâ (ïðèëîæåíèå), ïîëüçóþùóþñÿ íàèáîëüøèì ñïðîñîì íàñåëåíèÿ. Äàííàÿ íîìåíêëàòóðà ñîãëàñîâàíà ñ ýêñïåðòàìè êîíñóëüòàòèâíîãî ñîâåòà - ðóêîâîäèòåëÿìè ãîñóäàðñòâåííûõ óíèòàðíûõ àïòå÷íûõ ïðåäïðèÿòèé.

Ðóêîâîäèòåëÿì ãîñóäàðñòâåííûõ óíèòàðíûõ àïòå÷íûõ ïðåäïðèÿòèé ãîðîäà Ìîñêâû íåîáõîäèìî îáåñïå÷èòü ðåàëèçàöèþ äàííîãî ïðåäëîæåíèÿ ñîãëàñíî ðàçúÿñíåíèþ, ïîäãîòîâëåííîìó ðàáî÷åé ãðóïïîé ïî ðåîðãàíèçàöèè ãîñóäàðñòâåííîé àïòå÷íîé ñåòè, î ïîðÿäêå âûïîëíåíèÿ.

 

Ðóêîâîäèòåëü

Äåïàðòàìåíòà çäðàâîîõðàíåíèÿ

À.Ï.ÑÅËÜÖÎÂÑÊÈÉ

 

 

 

 

 

Ïðèëîæåíèå N 1

 

ÌÀÊÑÈÌÀËÜÍÛÅ ÐÎÇÍÈ×ÍÛÅ ÖÅÍÛ

 

Òîðãîâîå íàèìåíîâàíèå             

Ìàêñèìàëüíàÿ
ðîçíè÷íàÿ 
öåíà (â òîì
÷èñëå ÍÄÑ)

ÀÄÅËÜÔÀÍ-ÝÇÈÄÐÅÊÑ òàá. N 10 Novartis pharma       

8,5   

ÀËËÎÕÎË òàá. N 24 Ìîñõèìôàðìïðåïàðàòû             

7,5   

ÀËÌÀÃÅËÜ ñóñïåíçèÿ 170 ìë N 1 Actavis             

47,5   

ÀÌÁÐÎÁÅÍÅ òàá. 30 ìã N 20 Ratiopharm International

43     

ÀÌÏÈÎÊÑ-ÍÀÒÐÈÉ ïîðîøîê äëÿ âíóòðèâåííîãî ðàñòâîðà 
500 ìã N 1 Áðûíöàëîâ-À                            

6,5   

ÀÍÀËÜÃÈÍ òàá. 500 ìã N 10 Ìîñêîâñêàÿ ôàðìôàáðèêà  

2     

ÀÐÁÈÄÎË-ËÝÍÑ òàá. ï/î 100 ìã N 10 Ìàñòåð ËÅÊ      

145    

ÀÐÁÈÄÎË-ËÝÍÑ òàá. ï/î 50 ìã N 10 Macòåð ËÅÊ       

87     

ÀÑÊÎÐÓÒÈÍ òàá. N 50 Ôàðìñòàíäàðò-Óôàâèòà          

13,5   

ÀÑÏÀÐÊÀÌ òàá. 350 ìã N 50 Ëóãàíñêèé ÕÔÇ           

11,59  

ÀÒÅÍÎËÎË ÍÈÊÎÌÅÄ òàá. ï/î 50 ìã N 30 Nycomed      

42,9   

ÁÈÎÏÀÐÎÊÑ àýðîçîëü 400 äîç 20 ìë N 1 Servier      

210     

ÁÐÎÌÃÅÊÑÈÍ 8 ÁÅÐËÈÍ-ÕÅÌÈ äðàæå 8 ìã N 25 Berlin-  
Chemie/Menarini group                             

19     

ÂÀËÅÐÈÀÍÛ ÝÊÑÒÐÀÊÒ òàá. ï/î 20 ìã N 50 Áîðèñîâñêèé
Çàâîä Ìåäïðåïàðàòîâ                               

9,7   

ÂÀËÈÄÎË òàá. ñóáëèíãâàëüíûå 60 ìã N 10            
Ôàðìñòàíäàðò-Ëåêñðåäñòâà                          

3,4   

ÂÀËÎÊÎÐÄÈÍ êàïëè äëÿ ïðèåìà âíóòðü 50 ìë N 1 Krewel
Meuselbach GmbH                                   

70     

ÂÀËÎÑÅÐÄÈÍ ôë. 25 ìë N 1 Ìîñêîâñêàÿ ôàðìôàáðèêà   

12     

ÃÅÏÀÐÈÍÎÂÀß ÌÀÇÜ ìàçü 25 ã Íèæôàðì                

15     

ÃÈÏÎÒÈÀÇÈÄ òàá. 25 ìã N 20 Sanofi-Synthelabo      

55     

ÃËÀÊÑÅÍÍÀ òàá. N 10 GSK Pharmaceuticals           

5,7   

ÄÅÐÈÍÀÒ ðàñòâîð äëÿ íàðóæíîãî ïðèìåíåíèÿ 0.25% - 10
ìë N 1 Òåõíîìåäñåðâèñ                             

105,6   

ÄÈÀÇÎËÈÍ äðàæå 100 ìã N 10 Ùåëêîâñêèé âèòàìèííûé  
çàâîä                                             

8,58  

ÄËßÍÎÑ ñïðåé íàçàëüíûé 0.1% 10 ìë N 1 Novartis    
Consumer                                          

55     

ÈÌÎÄÈÓÌ êàïñ. 2 ìã N 20 Janssen-Cilag             

150     

ÉÎÄ ðàñòâîð ñïèðòîâîé 5% - 10 ìë N 1 Ìîñêîâñêàÿ   
ôàðìôàáðèêà                                       

5,5   

ÊÀÂÈÍÒÎÍ òàá. 5 ìã N 50 Gedeon Richter            

125     

ÊÀÏÎÒÅÍ òàá. 25 ìã N 40 Àêðèõèí                   

125     

ÊÀÐÑÈË äðàæå 35 ìã N 80 Sopharma                  

78     

ÊÀÔÔÅÒÈÍ òàá. N 10 Ñîòåêñ                         

50      

ÊÅÒÀÍÎÂ òàá. 10 ìã N 10 Ranbaxy laboratories Ltd. 

23     

ÊÎËÄÀÊÒ ÔËÞ ÏËÞÑ êàïñ. ðåòàðä N 10 Ranbaxy        
laboratories Ltd.                                 

42     

ÊÎÐÂÀËÎË êàïëè îðàëüíûå 25 ìë N 1 Ìîñêîâñêàÿ      
ôàðìôàáðèêà                                       

6,4   

ËÈÍÅÊÑ êàïñ. N 16 LEK                             

120     

ÌÀÀËÎÊÑ ñóñïåíçèÿ îðàëüíàÿ 15 ìë N 1 Aventis      

6     

ÌÅÇÈÌ ÔÎÐÒÅ òàá. ï/î N 20 Berlin-Chemie/Menarini  
group                                              

40     

ÌÅÒÐÎÃÈË ÄÅÍÒÀ ãåëü 20 ã Unique pharmaceutical    
laboratories                                      

31,9   

ÍÀÇÈÂÈÍ êàïëè (ôë. ñ ïèïåòêîé) 0.05% - 10 ìë N 1  
Nycomed                                           

55     

ÍÀÒÐÈß ÕËÎÐÈÄ ðàñòâîð äëÿ èíúåêöèé èçîòîíè÷åñêèé  
0.9% - 200 ìë N 1 Êðàñôàðìà                       

25,7   

ÍÀÔÒÈÇÈÍ êàïëè íàçàëüíûå 0.1% 10 ìë Ëåêêî         

6     

ÍÈÒÐÎÊÎÐ òàá. 0.5 ìã N 40 Ôàðìñòàíäàðò-Îêòÿáðü    

13     

ÍÈÒÐÎÑÎÐÁÈÄ òàá. 10 ìã N 25 Òàòõèìôàðìïðåïàðàòû   

6     

ÍÎ-ØÏÀ òàá. 40 ìã N 20 Sanofi-Synthelabo          

48     

ÍÎ-ØÏÀ òàá. 40 ìã N 100 Sanofi-Synthelabo         

135     

ÎÁËÅÏÈÕÎÂÎÅ ÌÀÑËÎ ñâå÷è N 10 Íèæôàðì              

25     

ÎÌÅÇ êàïñ. 20 ìã N 30 Dr.Reddy's                  

156     

ÏÀÍÀÍÃÈÍ äðàæå N 50 Gedeon Richter                

52     

ÏÈÊÀÌÈËÎÍ òàá. 50 ìã N 30 Àêðèõèí                 

45     

ÏÈÍÎÑÎË êàïëè íàçàëüíûå 10 ìë N 1 Zentiva         

29     

ÐÀÍÈÒÈÄÈÍ òàá. ï/î 150 ìã N 20 Òþìåíñêèé ÕÔÇ      

23     

ÐÅÍÈÒÅÊ òàá. 10 ìã N 14 Merk Sharp & Dome         

80,8   

ÐÈÁÎÊÑÈÍ òàá. 200 ìã N 50 Ôàðì-öåíòð/Áèîñèíòåç    

17,7   

ÑÀÍÎÐÈÍ ýìóëüñèÿ íàçàëüíàÿ 0.1% 10 ìë IVAX        

30     

ÑÅÍÀÄÅ òàá. N 20 Cipla Ltd.                       

6,4   

ÑÈÍÀÔËÀÍ ìàçü 0.025% - 15 ã N 1 Íèæôàðì           

13     

ÑÌÅÊÒÀ ïîðîøîê(ïàêåòû) 3 ã N 10 Beaufour-Ipsen    
international                                      

118     

ÑÏÀÇÃÀÍ òàá. 500 ìã N 20 Wockhardt Ltd.           

29     

ÑÏÀÇÌÀËÃÎÍ òàá. N 20 Actavis                      

31     

ÑÓËÜÔÀÖÈË-ÍÀÒÐÈÉ êàïëè ãëàçíûå /â êîìïëåêòå ñ     
êðûøêîé-êàïåëüíèöåé/ 20% - 5 ìë Ôàðì-öåíòð/Ñèíòåç 
ÀÊΠ                                              

18,8   

ÒÀÂÅÃÈË òàá. 1 ìã N 20 Novartis Consumer          

68     

ÒÀÓÔÎÍ êàïëè ãëàçíûå 4% - 5 ìë Ëåêêî              

5,3   

ÒÅÌÏÀËÃÈÍ òàá. ï/î N 20 Sopharma                  

30     

ÒÐÎÊÑÅÂÀÇÈÍ ãåëü 2%-40 ã N 1 Actavis              

45     

ÓÃÎËÜ ÀÊÒÈÂÈÐÎÂÀÍÍÛÉ òàá. 250 ìã N 10 Ôàðìñòàíäàðò-
Ëåêñðåäñòâà                                       

1,8   

ÓÏÑÀÐÈÍ ÓÏÑÀ Ñ ÂÈÒÀÌÈÍÎÌ Ñ òàá. øèï. N 10 UPSA    

39     

ÔÀËÈÌÈÍÒ äðàæå 25 ìã N 20 Berlin-Chemie/Menarini  
group                                             

62     

ÔÀÐÈÍÃÎÑÅÏÒ òàá. 10 ìã N 20 Terapia SA            

55     

ÔÀÑÒÓÌ ãåëü 2.5% 50 ã N 1 Berlin-Chemie/Menarini  
group                                             

145     

ÔÅÑÒÀË äðàæå N 20 Aventis                         

30,5   

ÔÒÀËÀÇÎË òàá. 500 ìã N 10 Ìîñõèìôàðìïðåïàðàòû     

9     

ÔÓÐÀÇÎËÈÄÎÍ òàá. 50 ìã N 10 Äàëüõèìôàðì           

1,6   

ÕËÎÐÃÅÊÑÈÄÈÍÀ ÁÈÃËÞÊÎÍÀÒ ðàñòâîð 0.05% 100 ìë     
Ðîñáèî                                            

9,49  

ÖÈÍÍÀÐÈÇÈÍ òàá. 25 ìã N 50 Sopharma               

10     

ÖÈÒÐÀÌÎÍ òàá. N 6 Ìîñêîâñêàÿ ôàðìôàáðèêà          

1,1   

ÝÍÀËÀÏÐÈË òàá. 10 ìã N 20 Ñîòåêñ                  

15     

ÝÍÀÏ òàá. 10 ìã N 20 KRKA                         

68     

ÝÑÏÓÌÈÇÀÍ êàïñ. 40 ìã N 25 Berlin-Chemie/Menarini 
group                                              

94     

ÝÑÑÅÍÖÈÀËÅ Í êàïñ. 300 ìã N 30 Aventis            

190     

ÃÀËÀÇÎËÈÍ êàïëè íàçàëüíûå 0.1% - 10 ìë N 1 Warszaw
pharmaceutical work Polfa                         

25     

ÑÒÐÅÏÒÎÖÈÄ ïîðîøîê 2 ã Ëþìè ÎÎΠ                  

1,8   

ÄÈÁÀÇÎË òàá. 20 ìã N 10 Ôàðìàêîí                  

1,25  

ÎÒÐÈÂÈÍ ñïðåé íàçàëüíûé 0.1% - 10 ìë N 1 Novartis 
Consumer                                          

89     

 

ÏÆÍÂËÑ                                                         25%

 

ÀÌÏÈÖÈËËÈÍÀ ÒÐÈÃÈÄÐÀÒ òàá. 250 ìã N 24            
Ìîñõèìôàðìïðåïàðàòû                               

15,09  

ÀÖÅÒÈËÑÀËÈÖÈËÎÂÀß ÊÈÑËÎÒÀ òàá. 500 ìã N 10        
Ìîñêîâñêàÿ ôàðìôàáðèêà                            

1,64  

ÁÈÑÅÏÒÎË òàá. 480 ìã N 20 Polfa Pabianickie zaklady
farmaceutyczne SA                                 

44,96  

ÂÎËÜÒÀÐÅÍ ýìóëüãåëü 1% 20 ã N 1 Novartis Consumer 

88,28  

ÄÈÊËÎÔÅÍÀÊ ãåëü 1% 40 ã Hemofarm D.D.             

49,51  

ÇÎÂÈÐÀÊÑ êðåì 5% - 2 ã N 1 GSK Consumer Healthcare

144,91  

ÊËÀÐÈÒÈÍ òàá. 10 ìã N 10 Schering-Plough          

164,45  

ÊËÀÔÎÐÀÍ ïîðîøîê 1 ã N 1 Aventis                  

83,33  

ÊËÎÒÐÈÌÀÇÎË êðåì 1% - 20 ã N 1 GSK Pharmaceuticals

42,50  

ÍÈÑÒÀÒÈÍ òàá. ï/î 500000 ÅÄ N 20 Ôàðì-öåíòð/      
Áèîñèíòåç                                         

21,19  

ÍÎÂÎÊÀÈÍ ðàñòâîð äëÿ èíúåêöèé 0.5% - 5 ìë N 10    
Îðãàíèêà                                          

12,50  

ÍÎÎÒÐÎÏÈË êàïñ. 400 ìã N 60 Pliva                 

146,99  

ÎÐÒÎÔÅÍ ìàçü 2% - 30 ã N 1 Ìîñêîâñêàÿ ôàðìôàáðèêà 

13,13  

ÑÎËÏÀÄÅÈÍ òàá. ðàñòâîðèìûå N 12 GSK Consumer      
Healthcare                                         

75,14  

ÑÓÏÐÀÑÒÈÍ òàá. 25 ìã N 20 Egis                    

75,49  

ÒÐÈÕÎÏÎË òàá. 250 ìã N 20 Polpharma               

51,70  

ÒÐÎÌÁÎ ÀÑÑ òàá. ï/î 50 ìã N 30 Lannacher heimittel
GmbH                                              

42,63  

ÔËÞÊÎÑÒÀÒ êàïñ. 150 ìã N 1 Ìàñòåð ËÅÊ             

144,38  

ÖÅÔÀÇÎËÈÍ ÍÀÒÐÈß ïîðîøîê äëÿ ïðèãîòîâëåíèÿ        
èíúåêöèîííîãî ðàñòâîðà 1 ã N 1 Êðàñôàðìà          

16,50  

 

 



Âñå íîðìàòèâíî-ïðàâîâûå àêòû ïî ìåäèöèíå // Çäðàâîîõðàíåíèå, çäîðîâüå, çàáîëåâàíèÿ, ëå÷åíèå, ëåêàðñòâà, äîêòîðà, áîëüíèöû //

Ðåéòèíã@Mail.ru ßíäåêñ öèòèðîâàíèÿ

Copyright © Ìåäèöèíñêèé èíôîðìàöèîííûé ðåñóðñ www.hippocratic.ru, 2012 - 2024